Seok‐Goo Cho

机构：St. Mary's Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea · ORCID：0000-0002-5429-4839

发表论文 537 篇 · 总被引 7966 次 · h-index 41

代表论文

• Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies (2025 · Blood · 被引 2)
• Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes (2026 · Annals of Hematology · 被引 1)
• Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL) (2025 · Blood · 被引 1)
• Real-World Outcome of Defibrotide Treatment for Severe Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation (2025 · Transplantation and Cellular Therapy · 被引 1)
• Survival Machine Learning Methods Improve Prediction of Histologic Transformation in Follicular and Marginal Zone Lymphomas (2025 · Cancers · 被引 1)
• Impact of <i>KMT2A</i> Rearrangement on Peripheral T‑Cell Lymphoma, Not Otherwise Specified, and Angioimmunoblastic T‑Cell Lymphoma (2025 · Preprints.org · 被引 1)